Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Cooke & Bieler LP

Cooke & Bieler LP decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 419,637 shares of the medical research company's stock after selling 7,130 shares during the quarter. Cooke & Bieler LP owned 0.85% of Charles River Laboratories International worth $63,164,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CRL. D1 Capital Partners L.P. purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at approximately $172,752,000. Assenagon Asset Management S.A. lifted its position in shares of Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock valued at $85,811,000 after buying an additional 538,792 shares in the last quarter. Norges Bank purchased a new position in Charles River Laboratories International in the 4th quarter valued at $98,886,000. Wellington Management Group LLP lifted its holdings in Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new position in Charles River Laboratories International in the 4th quarter valued at $56,820,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CRL. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Mizuho cut their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their target price for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Evercore ISI raised their target price on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Finally, Barclays raised their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $174.54.

Charles River Laboratories International Stock Down 1.4%

Shares of CRL traded down $2.15 during midday trading on Friday, hitting $154.55. The company had a trading volume of 493,642 shares, compared to its average volume of 1,037,944. The company's 50-day simple moving average is $147.42 and its 200-day simple moving average is $150.35. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market capitalization of $7.59 billion, a P/E ratio of -237.77, a P/E/G ratio of 5.23 and a beta of 1.49. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The firm's revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.27 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).